Platelet Rich Plasma Market is Witness Massive Surge as U.S.-based Industry Leader Generex Biotechnology Corporation acquires Medisource Partners
Platelet-rich
plasma is a coagulated blood-rich polymer, made from extracted platelets.
Extracted platelets are normally coagulated by monocytes or lymphocytes with
fibrin. Platelets are also commonly injected into the body's bloodstream to
support tissue healing following tissue surgery. Platelet-rich plasma has been
found effective against bleeding disorders. It also helps reduce the risk of
deep vein thrombosis (DVT) in patients with high blood pressure and in those
taking anticoagulants. It may also reduce the risk of pulmonary embolism (PE),
which is blood clots that enter the lungs and pulmonary system. In the chest,
the clot can stop or limit the flow of blood to the heart. PE often leads to
cardiac arrest and death.
Increasing
cosmetic surgeries is expected to drive growth of the global platelet
rich plasma market during the forecast period.
Cosmetic surgeries refer to surgical specialty involving the restoration,
alteration, or reconstruction of the human body. According to the International
Society of Aesthetic Plastic Surgery (ISAPS), in 2018, around 128,398 cosmetic
procedures in Thailand and 1,036,618 procedures in Mexico were carried out.
Hence, these factors are expected to drive growth of the global platelet rich
plasma market during the forecast period. Furthermore, increasing prevalence of
cosmetic surgeries is expected to boost the global platelet rich plasma market
growth over the forecast period.
However,
uncertainty regarding the efficiency of platelet-rich plasma products combined
with the high cost of these products is expected to hinder the global platelet
rich plasma market growth over the forecast period. Besides, continuous R&D
activities in the field of plasma-rich bioactive molecules can present
lucrative growth opportunities in the global platelet rich plasma market in the
near future. Among regions, North America is expected to hold a dominant
position in the global platelet rich plasma market during the forecast period.
This is owing to increasing number of people suffering from orthopedic
disorders. Furthermore, Asia Pacific is expected to register a robust growth
rate over the forecast period, owing to rising number of cosmetic surgeries
facial features in emerging economies such as Thailand, India, and South Korea.
Key players
operating in the global platelet rich plasma market are Estar Technologies
Ltd., Arthrex, Inc., Generex Biotechnology Corporation, Stryker Corporation,
Regen Lab S.A., Johnson and Johnsons Ltd., CollPlant, Zimmer Biomet Holdings
Inc., Medira Ltd., Terumo Corporation, and Glofinn Oy.
For
instance, in July 2019, Generex Biotechnology Corporation, a U.S.-based
healthcare company, acquired Medisource Partners, a provider of medical and
surgical products to process bone marrow aspirates and platelet rich plasma biologics.
Comments
Post a Comment